[7] Following the receipt of his doctorate, Levy completed a postdoctoral fellowship with Prof. Paras N. Prasad at the Institute for Lasers, Photonics, and Biophotonics at SUNY Buffalo in the United States.

In 2019 the company received approval to sell NBTXR3 in Europe under the brand name Hensify® for the treatment of soft tissue sarcomas of the extremities and trunk wall.

[17][18][19] As Nanobiotix grew, Levy became increasingly frustrated at the struggles nanomedicine companies faced in gaining visibility and support in the European Union.

To advocate for nanomedical development, Levy joined the European Technology Platform Nanomedicine (ETPN) in 2012 and was elected vice president.

[20][21][22] Levy is a founding member of the ETPN Translation Advisory Board, which has supported 109 European biotech entrepreneurs in launching their companies.